Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review

Maturitas

Volumn 72, Issue 4, 2012, Pages 269-276

  Ilic, Dragan ^a   Misso, Marie ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Benign prostatic hyperplasia; Lycopene; Prostate cancer; Systematic review

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; GLUCOSE; ISOFLAVONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYC O MATO; LYCOPENE; LYCORED; PROSTATE SPECIFIC ANTIGEN; RETINOL ACETATE; SELENATE; SOLGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

AMERICAN UROLOGICAL ASSOCIATION BENIGN PROSTATIC HYPERPLASIA SCALE; ANTIOXIDANT ACTIVITY; CANCER MORTALITY; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; HUMAN; INCIDENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; MICTURITION; NATIONAL INSTITUTES OF HEALTH CHRONIC PROSTATITIS SYMPTOM INDEX; NOCTURIA; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; CAROTENOIDS; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84863776568     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.04.014     Document Type: Review

References (34)

1. Wilt T, Ishani A. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 1998;(1), http://dx.doi.org/10.1002/ 14651858.CD001044. Art. No.: CD001044.
2. Auffenberg G, Helfan B, McVary K. Established medical therapy for benign prostatic hyperplasia. Urological Clinics of North America 2009;36:443-59.
3. Berry S, Coffey D, Walsh P, Ewing L. The development of human benign prostatic hyperplasia with age. Journal of Urology 1984;132:474-9. (Pubitemid 14026148)
4. Schwarz S, Obermuller-Jevic U, Hellmis E, Koch W, Jacobi G, Biesalski H. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. Journal of Nutrition 2008;138:49-53.
5. McVary K, Roehrborn C, Avins A, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology 2011;185:1793-803.
6. Coyne K, Sexton C, Thompson C, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU International 2009;104:352-60.
7. Tacklind J, Fink H, MacDonald R, Rutks I, Wilt T. Finasteride for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2010;(10), http://dx.doi.org/10.1002/14651858.CD006015.pub3. Art. No.: CD006015.
8. Wilt T, MacDonald R, Hagerty K, Schellhammer P, Kramer B. 5-Alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database of Systematic Reviews 2008;(2), http://dx.doi.org/10.1002/14651858.CD007091. Art. No.: CD007091.
9. Hoffman R, MacDonald R, Wilt T. Laser prostatectomy for benign prostatic obstruction. Cochrane Database of Systematic Reviews 2000;(1), http://dx.doi.org/10.1002/14651858.CD001987.pub2. Art. No.: CD001987.
10. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61:69-90.
11. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: an updated Cochrane systematic review. BJU International 2011;107:882-91.
12. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2010;(9), http://dx.doi.org/10.1002/ 14651858.CD004720.pub2. Art. No.: CD004720.
13. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on prostate cancer part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 2011;59:61-71.
14. Ilic D, Maloney S, Green S. Guiding users to quality information about osteoarthritis on the Internet: a pilot study. Telemedicine Journal and e-Health: The Official Journal of the American Telemedicine Association 2005;11(6):703-6. (Pubitemid 43227826)
15. Beebe-Dimmer J, Wood D, Gruber S, et al. Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology 2004;63:282-7. (Pubitemid 38234419)
16. Chan J, Gann P, Giovannucci E. Role of diet in prostate cancer development and progression. Journal of Clinical Oncology 2005;23:8152-60. (Pubitemid 46211548)
17. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Archives of Biochemical & Biophysics 2004;430:127-34. (Pubitemid 39119787)
18. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiology, Biomarkers & Prevention 2004;13:340-5. (Pubitemid 38737456)
19. Giovannucci E. Tomato products, lycopene and prostate cancer: a review of the epidemiological literature. Journal of Nutrition 2005;135:2030S-1S. (Pubitemid 41099768)
20. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
21. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011.
22. Review manager (RevMan) version 5.0 for windows. Copenhagen: The Nordic Cochrane Centre.
23. Ansari M, Gupta N. A comparison of lycopene and orchidectomy vs. orchidectomy alone in the management of advanced prostate cancer. BJU International 2003;92:375-8. (Pubitemid 37100511)
24. Bunker C, McDonald A, Evans R, de la Rosa N, Boumosleh J, Patrick A. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutrition & Cancer 2007;57:130-7. (Pubitemid 47080084)
25. Grainger E, Schwartz S, Wang S, et al. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutrition & Cancer 2008;60:145-54. (Pubitemid 351451270)
26. Kucuk O, Sarkar F, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology, Biomarkers & Prevention 2001;10:861-8. (Pubitemid 32738598)
27. Mohanty N, Saxena S, Singh U, Goyal N, Arora R. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urologic Oncology: Seminars and Original Investigations 2005;23:383-5. (Pubitemid 41654502)
28. Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutrition & Cancer 2007;59:1-7. (Pubitemid 47549774)
29. van Breemen R, Shari. R, Viana M, et al. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prevention Research 2011;4:711-8.
30. Haseen F, Cantwell M, O'Sullivan J, Murray L. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer & Prostatic Diseases 2009;12:325-32.
31. Ilic D, Forbes K, Hassad C. Lycopene for the prevention of prostate cancer. Cochrane Database of Systematic Reviews 2011;(11), http://dx.doi.org/10. 1002/14651858.CD008007.pub2. Art. No.: CD008007.
32. Ahn J, Gammon M, Santella R, et al. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption and supplement use. American Journal of Epidemiology 2005;162:943-52. (Pubitemid 41619465)
33. Porrini M, Riso P. What are typical lycopene intakes? Journal of Nutrition 2005;135:2042S-5S. (Pubitemid 41099772)
34. Bailey R, Gahche J, Lenito C, et al. Dietary supplement use in the United States 2003-2006. Journal of Nutrition 2011;141:261-6.